Medical Affairs Reputations (EU5) [CLL]
How well does your CLL medical affairs team performance compare with the rest?
Is ‘moderately satisfied’ good enough? According to this latest survey of 150 medical oncologists and haematologists across the EU5 (UK, France, Germany, Italy and Spain) the performance of chronic lymphocytic leukaemia medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be achieved across the board. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied.
Use Medical Affairs Reputations: Chronic Lymphocytic Leukaemia 2017 (EU5) to discover how your team can better meet the high expectations of physicians at the frontline.
This report compares the current activities of medical affairs teams for the six leading CLL treatments from Novartis, Gilead, Roche, Janssen, AbbVie and Genmab. It shows:
Interested in the US market? Click here to see US Edition.
Request sample pages
Top Takeaways
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 7 medical affairs teams—answering important questions like:
What do physicians need?
We surveyed 150 medical oncologists and haematologists from the EU5 (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
All respondents:
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Is ‘moderately satisfied’ good enough? According to this latest survey of 150 medical oncologists and haematologists across the EU5 (UK, France, Germany, Italy and Spain) the performance of chronic lymphocytic leukaemia medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be achieved across the board. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied.
Use Medical Affairs Reputations: Chronic Lymphocytic Leukaemia 2017 (EU5) to discover how your team can better meet the high expectations of physicians at the frontline.
This report compares the current activities of medical affairs teams for the six leading CLL treatments from Novartis, Gilead, Roche, Janssen, AbbVie and Genmab. It shows:
- How physicians rate each team overall, and for 12 key medical affairs services.
- What is most important to physicians, plus what can be done better.
- How, and how often physicians want to meet with your team.
Interested in the US market? Click here to see US Edition.
Request sample pages
Top Takeaways
- Stand out or forgettable? One team strides ahead with 94% of physicians recalling an interaction within the last 6 months. For many, a monthly visit is preferable.
- Building confidence: How much do European physicians rely on medical affairs to answer questions about off-label usage? What are they spending more time talking about to medical affairs professionals than ever before?
- Fierce competition: One team tops the satisfaction table for every single medical affairs attribute. Which teams are closing in fast and where are they making the most impact?
- Pleased to see you: Face-to-face meetings are liked but are they the most preferred form of interaction? How do medical meetings and education events compare?
- Good news for all: Physicians praised every drug for at least 3 areas of support provided by medical affairs.
- Information is king: 39% of respondents want to know more from their medical affairs teams. What specifically are they asking for?
- Arzerra (ofatumumab; Novartis/Genmab)
- Gazyvaro (obinutuzumab; Roche)
- Imbruvica (ibrutinib; Janssen)
- MabThera (rituximab; Roche)
- Venclyxto (venetoclax; Roche/AbbVie)
- Zydelig (idelalisib; Gilead)
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 7 medical affairs teams—answering important questions like:
What do physicians need?
- How, and how often are they using your medical affairs team?
- What services do they consider most important?
- How often should you contact them? What channels are best?
- How memorable are your team’s interactions with doctors?
- How do doctors rank your team for performance and satisfaction in 12 key areas?
- How does your team compare to the competition—in each area, and overall?
- Are you delivering the services that are most important to doctors?
- Where do you need to improve?
- How can your team enhance its services?
We surveyed 150 medical oncologists and haematologists from the EU5 (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
All respondents:
- Have been practicing for between 3 and 35 years
- See at least 5 patients with CLL in a typical month
- Devote at least 50% of their time to direct patient care
- Have interacted with at least one listed product’s medical affairs team in the past 6 months.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. OBJECTIVES, SURVEY METHODOLOGY AND SAMPLING, PRODUCTS INCLUDED IN THE SURVEY, EXECUTIVE SUMMARY
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
3. INTERACTIONS IN THE PAST 6 MONTHS WITH MEDICAL AFFAIRS TEAMS FOR EACH PRODUCT
4. CURRENT FREQUENCY OF INTERACTIONS WITH MEDICAL AFFAIR TEAMS FOR EACH PRODUCT
5. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
6. EVALUATION OF OVERALL QUALITY OF INTERACTIONS WITH MEDICAL AFFAIRS TEAMS FOR EACH PRODUCT
7. ATTRIBUTE IMPORTANCE OF MEDICAL AFFAIRS TEAMS ROLES TO PHYSICIANS’ PRACTICE
8. EDGEMAP ANALYSIS – COMPETITIVE EVALUATION ON MEDICAL AFFAIRS TEAMS PERFORMANCE ON ATTRIBUTES
9. COMPETITIVE EVALUATION OF PHYSICIANS SATISFACTION OF INTERACTION WITH MEDICAL AFFAIRS TEAMS
10. NEED-GAP ANALYSIS BY PRODUCT
11. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
12. PREFERRED INTERACTION MEDIA AND FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
13. APPENDIX
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
3. INTERACTIONS IN THE PAST 6 MONTHS WITH MEDICAL AFFAIRS TEAMS FOR EACH PRODUCT
4. CURRENT FREQUENCY OF INTERACTIONS WITH MEDICAL AFFAIR TEAMS FOR EACH PRODUCT
5. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
6. EVALUATION OF OVERALL QUALITY OF INTERACTIONS WITH MEDICAL AFFAIRS TEAMS FOR EACH PRODUCT
7. ATTRIBUTE IMPORTANCE OF MEDICAL AFFAIRS TEAMS ROLES TO PHYSICIANS’ PRACTICE
8. EDGEMAP ANALYSIS – COMPETITIVE EVALUATION ON MEDICAL AFFAIRS TEAMS PERFORMANCE ON ATTRIBUTES
9. COMPETITIVE EVALUATION OF PHYSICIANS SATISFACTION OF INTERACTION WITH MEDICAL AFFAIRS TEAMS
10. NEED-GAP ANALYSIS BY PRODUCT
11. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
12. PREFERRED INTERACTION MEDIA AND FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
13. APPENDIX
